Latest News

Comment Period - Request for Information on Chemicals to be Considered by the Carcinogen Identification Committee

Request for information on chemicals under consideration for possible listing as known to the State to cause cancer: 5-chloro-ortho-toluidine and its hydrochloride (CASRN: 95-79-4); quinoline (CASRN: 91-22-5); 2,4,5-trimethylaniline and its hydrochloride (CASRN: 137-17-7).

Announcement of Wednesday, December 4, 1996 meeting of the Developmental and Reproductive Toxicant Identification Committee to consider inorganic arsenic, cadmium, mechanisms for removing chemicals from the Proposition 65 list, and prioritization.

Meeting of the Developmental and Reproductive Toxicant Identification Committee to consider listing inorganic arsenic and cadmium.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Dichlorvos (DDVP). These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

Comparative Risk Project.  One proposed way to prioritize environmental problems -- and develop viable solutions -- is through "comparative risk assessment."

OEHHA has provided a number of comments on the exposure assessment methodology and conclusions on the draft EAD for Fenoxaprop Ethyl. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Fenoxaprop Ethyl . These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Molinate. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Mevinphos. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.